Ocular Therapeutix, Inc. (OCUL) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 1.65B USD. 52-week range 6.23 to 16.44 USD. Data as of 2026-10-09.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that ...